StockData
UroGen Pharma Ltd. logo

UroGen Pharma Ltd. (URGN) stock

URGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$29.79−0.08 (-0.27%)

Close on Nov 18, 2026Market cap $1.46BP/E –Yield –

UroGen Pharma total assets

Total assets on the balance sheet at the end of each period.

UroGen Pharma's total assets was $252.59M at Jun 30, 2026. For fiscal 2025 it was $200.46M, down 29.8% from the year before. The highest annual figure on record is $285.71M in fiscal 2024.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$200.46M-29.8%
FY2024Dec 31, 2024$285.71M+60.2%
FY2023Dec 31, 2023$178.31M+31.5%
FY2022Dec 31, 2022$135.62M+13.3%
FY2021Dec 31, 2021$119.75M-1.9%
FY2020Dec 31, 2020$122.01M-39.7%
FY2019Dec 31, 2019$202.39M+95.4%
FY2018Dec 31, 2018$103.56M+37.1%
FY2017Dec 31, 2017$75.55M+227.7%
FY2016Dec 31, 2016$23.06M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$252.59M+21.0%
Q1 FY2026Mar 31, 2026$253.69M+2.5%
Q4 FY2025Dec 31, 2025$200.46M-29.8%
Q3 FY2025Sep 30, 2025$185.05M-38.7%
Q2 FY2025Jun 30, 2025$208.72M-25.9%
Q1 FY2025Mar 31, 2025$247.62M+23.5%
Q4 FY2024Dec 31, 2024$285.71M+60.2%
Q3 FY2024Sep 30, 2024$301.94M+55.9%
Q2 FY2024Jun 30, 2024$281.85M+195.6%
Q1 FY2024Mar 31, 2024$200.57M+77.6%
Q4 FY2023Dec 31, 2023$178.31M+31.5%
Q3 FY2023Sep 30, 2023$193.63M+50.7%
Q2 FY2023Jun 30, 2023$95.36M-34.7%
Q1 FY2023Mar 31, 2023$112.95M-31.8%
Q4 FY2022Dec 31, 2022$135.62M+13.3%
Q3 FY2022Sep 30, 2022$128.47M-4.6%
Q2 FY2022Jun 30, 2022$146.14M-5.0%
Q1 FY2022Mar 31, 2022$165.72M+70.1%
Q4 FY2021Dec 31, 2021$119.75M-1.9%
Q3 FY2021Sep 30, 2021$134.60M-3.8%
Q2 FY2021Jun 30, 2021$153.77M-4.5%
Q1 FY2021Mar 31, 2021$97.41M-41.6%
Q4 FY2020Dec 31, 2020$122.01M-39.7%
Q3 FY2020Sep 30, 2020$139.89M-38.3%
Q2 FY2020Jun 30, 2020$161.08M-32.5%
Q1 FY2020Mar 31, 2020$166.93M-33.8%
Q4 FY2019Dec 31, 2019$202.39M+95.4%
Q3 FY2019Sep 30, 2019$226.75M+101.5%
Q2 FY2019Jun 30, 2019$238.57M+96.3%
Q1 FY2019Mar 31, 2019$252.05M+94.8%
Q4 FY2018Dec 31, 2018$103.56M+37.1%
Q3 FY2018Sep 30, 2018$112.56M+388.2%
Q2 FY2018Jun 30, 2018$121.50M–
Q1 FY2018Mar 31, 2018$129.40M–
Q4 FY2017Dec 31, 2017$75.55M–
Q4 FY2016Dec 31, 2016$23.06M–

More UroGen Pharma figures

See a number that looks wrong?